Skip to main navigation Skip to search Skip to main content

Flavin-containing monooxygenase 2 confers cardioprotection in ischemia models through its disulfide bond catalytic activity

  • Qingnian Liu
  • , Jiniu Huang
  • , Hao Ding
  • , Yue Tao
  • , Jinliang Nan
  • , Changchen Xiao
  • , Yingchao Wang
  • , Rongrong Wu
  • , Cheng Ni
  • , Zhiwei Zhong
  • , Wei Zhu
  • , Jinghai Chen
  • , Chenyun Zhang
  • , Xiao He
  • , Danyang Xiong
  • , Xinyang Hu*
  • , Jian’an Wang*
  • *Corresponding author for this work
  • Zhejiang University
  • Cardiovascular Key Laboratory of Zhejiang Province
  • East China Normal University
  • State Key Laboratory of Transvascular Implantation Devices

Research output: Contribution to journalArticlepeer-review

Abstract

Myocardial infarction (MI) is characterized by massive cardiomyocyte (CM) death and cardiac dysfunction, and effective therapies to achieve cardioprotection are greatly needed. Here, we report that flavin-containing monooxygenase 2 (FMO2) levels were markedly increased in CMs in both ex vivo and in vivo models of ischemic injury. Genetic deletion of FMO2 resulted in reduced CM survival and enhanced cardiac dysfunction, whereas CM-specific FMO2 overexpression conferred a protective effect in infarcted rat hearts. Mechanistically, FMO2 inhibited the activation of ER stress–induced apoptotic proteins, including caspase 12 and C/EBP homologous protein (CHOP), by downregulating the unfolded protein response pathway. Furthermore, we identified FMO2 as a chaperone that catalyzes disulfide bond formation in unfolded and misfolded proteins through its GVSG motif. GVSG-mutated FMO2 failed to catalyze disulfide bond formation and lost its protection against ER stress and CM death. Finally, we demonstrated the protective effect of FMO2 in a human induced pluripotent stem cell–derived CM model. Collectively, this study highlights FMO2 as a key modulator of oxidative protein folding in CMs and underscores its therapeutic potential for treating ischemic heart disease.

Original languageEnglish
Article numbere177077
JournalJournal of Clinical Investigation
Volume134
Issue number24
DOIs
StatePublished - 16 Dec 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Flavin-containing monooxygenase 2 confers cardioprotection in ischemia models through its disulfide bond catalytic activity'. Together they form a unique fingerprint.

Cite this